Patents Represented by Attorney, Agent or Law Firm Mary E. McCarthy
  • Patent number: 7491728
    Abstract: The pyrimidinone compounds are disclosed. Methods of preparing the pyrimidinone compounds are also disclosed.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: February 17, 2009
    Assignee: SmithKline Beecham Corp.
    Inventors: Irina V. Shcherbakova, Manuel F. Balanddrin, Guangfei Huang, Otto Geoffroy, John Fox, Robert Marquis, Dennis Shinji Yamashita, Juan Luengo, Wenyong Wang
  • Patent number: 7276521
    Abstract: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: October 2, 2007
    Assignee: Glaxo Group Limited
    Inventors: Jakob Busch-Petersen, Michael R. Palovich, Zehong Wan, Hongxing Yan, Chongjie Zhu
  • Patent number: 6825188
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: November 30, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Patent number: 6815457
    Abstract: A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]-benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterized in that it: (i) provides an infra red spectrum containing peaks at 1360, 1326, 1241, 714 and 669 cm−1; and/or (ii) provides a Raman spectrum containing peaks at 1581, 768, 670, 271 and 226 cm−1; and/or (iii) provides a solid-state nuclear magnetic resonance spectrum containing peaks at chemical shifts substantially as set out in Table I; and/or (iv) provides an X-ray powder diffraction (XRPD) pattern containing peaks substantially as set out in Table II; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: November 9, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Paul David James Blackler, Robert Gordon Giles, Michael Sasse
  • Patent number: 6806280
    Abstract: A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2, 4-dione, maleic acid salt (the “Polymorph”) characterized in that it provides: (i) an infra red spectrum containing peaks at 1763, 912, 856 and 709 cm−1; and/or (ii) a Raman spectrum containing peaks at 1762, 1284, 912 and 888 cm−1; and/or (iii) a solid-state 13C nuclear magnetic resonance spectrum containing peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or (v) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: October 19, 2004
    Assignees: SmithKline Beecham p.l.c., SmithKline Beecham (Cork) Limited
    Inventors: Paul David James Blackler, Christine Marie Browne, Timothy G. Coakley, Robert Gordon Giles, Gillian Morrissey
  • Patent number: 6803376
    Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, particularly quinolone resistant S. pnemoniae and rare H. influenzae strains.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: October 12, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Peter C. Appelbaum, Kim L. Credito, Todd Davies, Diane B. Hoellman, Linda M. Kelly, Glenn A. Pankuch
  • Patent number: 6800486
    Abstract: A novel method for the determination of amino acids by HPLC using pre-column derivatization is described. In this procedure, the aminno acids are derivatized with 2-chlorobenzoxazole to yield highly fluroresent N-(2-benzoxazolyl)-amino acids (BOX-AAs) for detection at very high sensitivity. Derivatives can also be detected using conventional UV detection methods. The BOX-AAs can be separated on a C18 reversed phase column for quantitative estimation. This method can be used for the preparation of N-(2-benzoxazolyl)-amino acids in large amounts.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: October 5, 2004
    Assignee: SmithKline Beecham Corporation
    Inventor: Kalyan R Anumula
  • Patent number: 6767922
    Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: July 27, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine Louisa Widdowson, Qi Jin
  • Patent number: 6750195
    Abstract: A compound which acts as an antagonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: June 15, 2004
    Assignee: SmithKline Beecham Corporation p.l.c.
    Inventors: Gareth John Sanger, Kay Alison Wardle
  • Patent number: 6723749
    Abstract: This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: April 20, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Siegfried B. Christensen, Daniel J. Mercer, Jia-Ning Xiang
  • Patent number: 6713502
    Abstract: Novel anti-infective and methods of using them are provided.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: March 30, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Dashyant Dhanak, Thomas Carr
  • Patent number: 6699889
    Abstract: A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: March 2, 2004
    Assignees: SmithKline Beecham p.l.c., SmithKline Beecham Laboratoires Pharmaceutiques
    Inventors: Antoine Michel Alain Bril, Robin Edwin Buckingham, Nassirah Khandoudi
  • Patent number: 6699879
    Abstract: The present invention provides phenyl urea and phenyl thiourea derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors, of formula (I) in which: Z represents oxygen or sulfur; and R1 to R7 represent various substituent groups; and pharmaceutically acceptable salts thereof. In particular, these compounds are of potential use in the treatment of obesity including obesity observed in Type 2(non-insulin-dependent) diabetes patients and/or sleep disorders.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: March 2, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Coulton, Amanda Johns, Roderick Alan Porter
  • Patent number: 6696457
    Abstract: Heterocycle condensed morphinoid derivatives of formula (I) have therapeutic utility as analgesics, in collagen disease, as anti-allergic and anti-inflammatory agents, brain cell protectants, in gastritis, diarrhoea, cardiovascular and respiratory diseases, cough, mental illness, epilepsy, for the preservation of organs during transplant operations, and for the treatment of those pathological conditions which customarily can be treated with agonists of the delta opioid receptor.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: February 24, 2004
    Assignees: SmithKline Beecham p.l.c., SmithKline Beecham S.p.A.
    Inventors: Stephen Edward Clarke, Giulio Dondio, Luca Francesco Raveglia, Silvano Ronzoni
  • Patent number: 6686475
    Abstract: Compounds of formula (I): or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A1 represents a substituted or unsubstituted aromatic heterocyclyl group; R1 represents a hydrocarbon atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R2 and R3 each represent hydrogen, or R2 and R3 together represent a bond; A2 represents a benzene ring having a total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: February 3, 2004
    Assignee: Beecham Group p.l.c.
    Inventor: Richard Mark Hindley
  • Patent number: 6680317
    Abstract: This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: January 20, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael R. Palovich, Katherine L. Widdowson, Hong Nie
  • Patent number: 6677354
    Abstract: Disclosed are compounds of formula (I): wherein: Y represents a group (CH2)n, wherein n represents 0, 1 or 2; R1 is phenyl, naphthyl, a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S; or a group NR3R4 wherein one of R3 and R4 is hydrogen or optionally substituted (C1-4)alkyl and the other is phenyl, naphthyl or a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S, or R3 and R4 together with the N atom to which they are attached form a 5 to 7-membered cyclic amine which has an optionally fused phenyl ring; any of which R1 groups may be optionally substituted; R2 represents phenyl or a 5- or 6-membered heteroaryl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heteroaryl group is substituted by R5, and further optional substituents; or R2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 3 heteroatoms selected from N, O
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: January 13, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Clive Leslie Branch, Christopher Norbert Johnson, Geoffrey Stemp, Kevin Thewlis
  • Patent number: 6673965
    Abstract: A compound of formula (I) wherein: R isopropyl; n is 0; R1 is naphthylmethyl; R2 is t-butyl; and R3 is methyl; is useful in the treatment of disorders mediated by s-CD23.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: January 6, 2004
    Assignee: SmithKline Beecham P.L.C.
    Inventors: John Gerard Ward, Andrew Faller
  • Patent number: 6670388
    Abstract: This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: December 30, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Robert A. Daines, Siegfired B. Christensen, IV, Jack D. Leber, Martha S. Head
  • Patent number: 6664278
    Abstract: The present invention provides a novel hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: December 16, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Michael John Sasse, Paul David James Blackler, David C. Lee